Dexcom’s Medicare Tipping Point: Can 25 Million Patients Reshape CGM Growth?

Dexcom Incorporated reported a second quarter of 2026 marked by 13% year-over-year revenue growth to $1.31 billion, with 12% organic growth excluding currency fluctuations and non-core revenues. The U.S. market represented a significant portion of revenues at $933 million, growing 11%, while international markets rose 19% to $375 million, driven notably by expanded access in regions such as France and Canada. The company cited strong new customer starts globally, including a quarter-over-quarter increase in the U.S., maintaining momentum in patient acquisition and market share. Product innovation and launches contributed to performance, including the ongoing rollout of the Dexcom G7 15-day continuous glucose monitoring (CGM) system, now integrated with all adult U.S. G7 users through pump compatibility. The company expects nearly half of its U.S. installed base to convert to this newer system by year-end, a transition reported as progressing in line with management’s expectations.